<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 173 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page172.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=173">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 173 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 173</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=173"><img src="../thumb/173.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>140 / 2020-04                                                     Blood and Haemopoeitic - 8.2 / 8.3
   malaise, jaund., vasc. pseudoaneurysm, haemarthros., syncope,   assess.by appropr. imag. techniq., seiz.at onset of stroke, hist.of   Interactions: Drugs that alter platel.funct./ affect coagulat.may
   dizzin., headache, epistax., haemoptys., ecchymos., haematoma.  prev. stroke/ser.head trauma within 3 mnths., combin.of prev. stroke   incr.bleed.risk.
   Special precautions: Only use with effect. contracept.in women   & diab.mellit., heparin admin.within 48 hrs. preced.onset.of stroke   See also MDR page 270.
   of childbear.potent., cross. placenta, secret.in breast milk of rats, con-  with elevat.aPTT at present., platelet count &lt;100 000/mm , systol.
                                                         3
   genit./ acquir.bleed.disords., uncontr.sev.arter. hypertens., act.ulcerat.  BP &gt; 180/ diastol.BP &gt; 110 mm Hg or aggress. managem. necess.to   STREPTASE, (Actor Pharma) Mirren [P/S]
   GI dis., rec.GI ulcerat., vasc. retinopathy, rec.intracran./intracerebr.   reduc.BP.to these limit., bld. gluc.&lt;2,78 /&gt; 22,2 mmol/L.  Streptokinase
   haemorrh., intraspin./intracerebr.vasc.abnorm., aft.brain/spin./oph-  Side effects: Bleed.poss.at any site poss.life threaten. /caus.per-  Indications: System.IV admin: Ac.transmur.MI (&lt; 12 hrs.old) with
   thalmolog.surg., bronchiectas. / pulm.bleed.hist., sev.ren.impairm.,   man.disabil/death, (i.e. superfic. bleed.eg.from recent.punct.sites/   persist.ST-segm.elev./rec.left bundle-branch block, DVT (&lt; 14 days
   risk of epidur./ spin.haematoma with neurax.anaesth. /spinal punct.   damage. bld.vess.or, intern.bleed at any site/body cavity) cholester.  old), ac. massive pulm.embol., ac.& subac.thrombos.of periph. arter.,
   which is incr.with indwell.epidur. cathet./concom.meds affect.haemo-  crystal embolisat.  chron.occlus.arter.dis.(&lt; 6 wks.old), occlus.of centr.retin.artery or vein
   stas/traumat or rep.epidur.or spinal punct., monit.neurax. anaesthes.   MI indicat: reperfus.dysrhythm.  (arter.occlus.&lt; 6 - 8 hrs. old/ven.occlus. &lt; 10 days old),
   pts.for S&S of neurolog.impairm., eval. risk vs.benef.of neurax.anaes-  MI/pulm.embol./ac.ischaem.stroke: IC haemorrh.  Loc.intracoron./intra-arter. & IV admin: Ac. MI for re-open.of
   thes.in thromboprophylax. anticoagulat./to be anticoagulat. pts., do   MI/pulm.embol.& ac.ischaem.stroke: anaphylactoid reacts., eye/  coron.vessels (&lt; 12 hrs.old), ac./ subac./ chron.thrombos.& embol.
   not withdr.epidur.cathet. earl. than 18 hrs.aft.last Xarelto admin.,   pericard./hepat./ pulm./pharyngeal/GI/rect.haemorrh., haematoma,   of periph.ven.& arter. vess.
   admin. not bef.6 hrs.aft.remov.of epidur.cathet., delay admin. for   embol., haemoptys., epistax., haematemes., melaen, mouth haemor-  (S4), INJ. X/31/131, H2863.
   24 hrs.if traumat.punct.occurs, monit. for bleed.complicat., consid.  rh., N&V, retroperitoneal haematoma, gingiv.bleed., ecchymos., hae-  782610-005: 750 000 iu, 1 vial, R2 158,22
   poss.bleed.in pres.of unexpl. Hb/BP decr., placent.chang.shown in   matur., UT haemorrh., inj./punct.site haemorrh., BP decr., body temp.  785369-007: 1 500 000 iu, 1 vial, R4 316,48
   rats & rabbits, signif.incr.pharmacolog.activ.in mod. hepat. impairm.,   incr., fat.embol., transfus., IC haemorrh. may be assoc.with neurolog.  Dosage: For IV/ intra-arterial.admin., durat.of ther. dep.on nature &
   elderly, Xarelto 15 & 20 also: discont. ther.at least 24 hrs.bef.invas.   sympts.incl.somnol./ aphas./ hemipares. & convuls.  extens. of vessel occlus. & diff. accord. to indicat.
   proced./ surg. if poss., cons.benef.vs.incr.bleed.risk if proced. can-  Warnings and special precautions: Safety in pregn.& lactat   Ac.transmur.MI with persist. ST-segm. elev./ rec. left bundle-
   not be delay., restart ther.as soon as poss. aft.proced.provid.adeq.  not est., dos.exceed 100 mg or 90 mg in ac. ischaem.stroke assoc.  branch block: System. IV admin: Short-term lysis for treatm. of acute
   homeostas.est., mod. ren.funct.impairm.with concom.meds. lead.   with incr.in intracran.bleed., att.to all potent.bleed.sites. (eg. recent   MI: 1,5 million IU within 60 min. Loc.intracoron.admin: Ac. MI: In-
   to incr. Xarelto plasma conc., limit.data in pts. with creatin.clear.&lt;   punct.sites), avoid.IM admin.& non-essent. handl. of pt.dur.treatm.,   tracoron.bolus of 20 000 IU on aveg.& maint. dos. of 2 000-4 000 IU/
   30 to 15 ml/min., not recomm. in pts.with creat.clear.&lt; 15 ml/min.  venepunct.perform.caref.& only as necess., use sites accessible to   min. over 30-90 mins. Tot. dos. max: 240 000 IU.
   due to no clinic.data, not recomm.with concom.azole-antimycot./HIV   man. compress. of 30 mins.if arter.punct.necess., with ac. MI an-  Ac./subac. & chron.thrombos./embol.of periph. ven.& arter.
   prot.inhibits., concom.strong CYP 3A4 induc., elev.INR, INR not to be   tiarrhythm.ther.to be avail., discont. immed. & any concom.hepar.  vessels & chron.occlus. arter. dis: System. IV admin.: Short-
   used to meas. Xarelto’s anticoag.activ., inadeq.anticoag. potent. dur.  in event of ser. bleed.& implem.appropr.act., haemostat.defect. incl.   term thrombolys. with periph.ven.& arter.vessel occlus./em-
   transit.from Xarelto to warfar.  those second.to sev.hepat./ren.dis., rec.IMI/ trauma, resuscit.card.  bol.: Init.dos: 250 000 IU within 30 mins. follow.by maint.dos of 1,5
   Interactions: Incr.syst.expos.with strong CYP3A4 & P-gp inhibit.,   massage, sept. thrombophlebit., occul.AV cannula at ser.infect. site,   million IU/hr over max. 6 hrs. The 6-hr infus.can be repeat.on follow.
   decr.in rivaroxaban AUC with strong CYP3A4 & P-gp induc.rifampicin,   incr.haemorrh.risk condits. With ac. MI & ac.pulm.embol: Also sys-  day depend.on therapeut.succ.of lysis. As alternat. to short-term lysis
   other strong CYP3A4 induc., incr.bleed.time with clopidrogrel, incr.  tolic BP &gt;160 mm Hg, advan.age. With ac.MI: Also dysrhythm.risk as-  a long-term lysis for treatm.of periph. occlus.may be consid.: Init.dos.
   AUC & C max.with ketoconazole/ ritonavir(600 mg 2x dly).  soc. with reperfus., concom.glycoprot.IIb/IIIa antagon. incr.bleed.risk,   of 250 000 IU giv. within 30 min follow.by maint.dos. of 100 000 IU/hr.
                                poss incr.thrombo-embol. events in pts.with left heart thombus. With   Durat.of ther.depend.on extens.& and localisat.of the vessel occlus.
                                ac. ischaem. stroke: Also mark.incr.risk.of IC haemorrh. as bleed.  In periph vessel occlus. the max.durat is 5 days.
   8.3    Fibrinolytics         occurs.predomin.into infarct. area, all situat.involv.high.haemorhh.  Loc. intracoron./ IV admin: Ac., subac.& chron. periph. thrombos.
                                                              & embol.: 1 000-2 000 IU in 3 - 5 min.interv. Durat.of admin.depends
                                risk, small asymptomat.aneurysm.of cerebr.vess., late time-treatm.
   ACTILYSE (MDR Listing)       onset, great.IC haemorrh.risk in acetylsalicyl. acid pre-treat.pts.partic.  on length & localisat. of vessel occlus. and amounts up to 3 hrs at
                                if treatm. delay.theref.admin.max.90 mg, treatm.not to be init. lat.than
                                                              max.tot.dos.of 120 000 IU.
   METALYSE (MDR Listing)       4,5 hrs.aft.sympt.onset,as posit. treatm.effs.decr.over time/mortality   Occlusions of central retinal arteries or veins: System. IV admin:
   ACTILYSE, Ing Pharm.[P/S] &  rate incr.with prior ASA treat,.& incr.symptomat.haemorrh.risk, monit.  Thrombos.of central retin. vessels: Limit lysis of arter.occlus.to
   Alteplase (recombin.human tiss.type plasminogen activator) in   BP dur.treatm.& up to 24 hrs necess., antihypertens.ther.recom.when   max. 24 hours & ven.occlus. to max.72 hs. If continuat.of thrombolys.
   2333 mg dry subst.           systol.BP &gt;180 mm Hg/diastol &gt;105 mm Hg, therapeut.benef.reduc.in   indicat.due to extens.thrombot.occlus. interrupt ther.for 1 day follow.
   Indications: Fibrinolyt.ther.in ac.MI within 6 hrs. of sympt.onset.,   pts. who had prior stroke/where diabet.uncontrol., do not treat mild   by admin.of a homolog. fibrinolyt.
   thrombolyt.treatm.in pts.with ac. massive pulmon.embol.& haemo-  strokes as risks outweigh expect. benefits, do not treat pts.with very   Ref.to prod.lit.for ther.contr.& foll-up treatm.
   dyn.instab., thrombolyt. treatm.of ac.ischaem.stroke init.within 4,5   sev.stroke as risk of intracerebr.haemorrh.& death high., consid. risk   Contraindicatons: Sev.allerg.reacts., exist./ recent intern.haemor-
   hrs.aft.onset.of stroke sympts.& aft.excl.of intracran. haemorrh.by   vs.benef.in pts with extens.infarct.as poor outcome a great.risk, reper-  rh., reduc.bld.coagulabilit. esp.spontan.fibrinolys.& extens.clott.dis-
   apprior,imag,techniq.        fus.of ischaem.area poss. induc.cerebr.oed.of infarct.area, due to incr.   ords., rec.CV insult./head trauma/trauma, rec.intracran. / intraspin.
   (S4) INFUS. U/31/229, U/32.4/230.  haemorrh.risk platel.aggregat.inhibit.should not be init.within 24 hrs.  surg., intracran.neoplasm, arterioven. malformat./aneurysm, known
   863548-008: 50 mg, 1 vial+ solvent, R9 555,35  foll.thrombolys.alteplase, avoid rigid cathet.use, limit.exper.in childr.  neoplasm with haemorrh. risk, ac.pancreatit., uncontrol. hypertens.
   Dosage: Use by exper.drs.in facilit.to monit. Std resuscitat.equipm.&   Drug interactions: No form.interact.stud.with meds. used dur.ac.MI   with systol.values above 200 mm Hg and/or diastol.values above
   meds.to be avail. Eval.benef. vs.risk. Admin.ASAP aft.sympt.onset.   performed but meds.affect. coagulat./those alter.platelet funct.may   100 mm Hg, grade III & IV hypertens.retin.changes, rec.implant.of
   No exper. with re-admiss.    incr.bleed. risk prior to/dur/aft.ther., concom.ACE inhibit.ther. enhanc.  vess. prosthes., simultan.treatm.with oral coags. (INR&gt;1.3), known
   Dil.to conc. 1 mg/mL.with provid.solv. Do not mix with other drugs.   anaphylact.react.risk  haemorrhag.diathes., depend. on proced. rec.maj.ops. 61h-101h
   Admin.with perfusor./pump pref.  See also MDR page 257.    post-op day, invas. ops.eg.rec.organ biopsy/long-term closed-
   MI: Start treatm.within 6 hrs as follows: 15 mg as IV bolus, 50 mg   METALYSE, Ing Pharm. [P/S] &  chest card.massage, prov./suspect.aort.dissect., sev. imp.liv./kidn.
   as infus.over 1st 30 mins., follow. by 35 mg infus.over 60 mins.until   Tenecteplase  funct., endocardit., pericardit., rec. cerebr.haemorrh., admin.dur.first
   max.dos.of 100 mg. Pts. below 65 kg: Adjust dos.as: 15 mg as IV   Indications: Thrombolyt.ther.in ac.MI as soon as poss.aft.sympt.  18 wks.of pregn. only if absol.necess.otherwise admin.dur. pregn.
   bolus, and 0,75 mg/kg bm over 30 mins.(max. 50 mg) follow.by an   onset but within 6–9 hrs.of sympt. onset.  only aft.caref.risk:benefit eval., safety in lactat.not est., safety &
   infus.0,5 mg/kg bm.over 60 mins. (max. 35 mg). Tot.dos.must not ex-  (S4) SOL FOR INJ. 34/31/0409, 0410, 34/32.4/0411. 5 mg/mL   effic.in childr.not est.
   ceed 1,5 mg/kg in pts.und.65 kg.  (once reconstit)         Side effects: Haemorrh.at inj.site, ecchymos., GI/ urogenit.bleed.,
   Adjunct.ther: Antithrombot.adjunct.ther.recomm. accord.to curr.  893007-003: 40 mg, 1 vial & pre-fill.syr, R19 242,71  epistax., min.to sev. haemorrh., developm.of antistreptokin.antibod.,
   guidelines for ST-elev.MI managem.  893013-005: 50 mg, 1 vial & pre-fill.syr, R21 444,00  allerg.-anaphylact.reacts incl.rash/flush./itch/ urticar./ angioneurot.
   Pulm.embol: Pulm.embol.diagnos.should be confirm.by object.  Dosage: Reconstit.vial contents using supplied pre-fill.syr. May   oed./dyspn./bronchosp/ hypotens., delay. allerg.reacts.incl.ser.sickn./
   means. Tot.dos of 100 mg admin. in 2 hrs., 10 mg.as IV bolus over 1-2   be admin.into pre-exist.0,9% NaCl IV line. Incompat.with dextr.  arthrit./ vasculit./nephrit/neuroallerg.sympts./ shock/resp. arrest,
   mins., 90 mg as IV infus.over 2 hrs. Pts.with body weight bel.65 kg:   sol. Admin.as sngl. IV bol.over about 5-10 secs.accord.to bm. Max.  neurolog.sympts.incl.dizzin./ confus./ paralys./hemipares/agitat./
   Tot.dos.must not exceed 1,5 mg/kg.  dos: 50 mg.            convuls.in context of cerebr.haemorrh./CV disords.with hypoperfus.
   Adjunct.ther: Aft.treatm.init.or resume heparin ther. when aPTT   &lt;60 kg: 30 mg, &gt; 60-&lt;70 kg: 35 mg, &gt; 70-&lt;80 kg: 40 mg, &gt; 80-&lt;90   of the brain, hypotens., tachycard., bradycard., ang.pect., heart fail.,
   value is less than twice upper limit of norm. Adjust.accord.to aPTT   kg: 45 mg, &gt; 90 kg: 50 mg.  cardiogen. shock, pericardit., pulm.oed., card.arrest, mitral insuffic.,
   value of betw. 50-70 secs. (1,5 to 2,5 fold of ref.val.)  Antithrombot.adjunct.ther: Recomm.accord.to curr. internat.guide-  pericard.effus., card.tamponade, myocard. rupt., crystal cholester.
   Ac.ischaem.stroke: Recomm.dos. 0,9 mg/kg (max. 90 mg) infus.  lines for ST-elevat.MI managem.  embol., recurr. ischaem., reinfarct, pulm./ periph. embol.,distal em-
   over 60 min.with 10% tot.dos. admin as init.IV bolus. Init.as early as   Contraindications: Hepat.dysfunct.incl.hepat. fail., cirrhos., port.  bolisat., GI disords., headache, back/musc. pain, chills &/rise in temp,
   poss.within 4,5 hrs. aft.onset.of sympts.& aft.excl.of IC haemorrh.by   hypertens.(oesophag.varices), act.hepatit., no studies avail.in imp.liv.  asthen./malaise., trans. elev.ser.transaminas./ bilirub.
   appropr.imag.techniques sensit.to the pres.of haemorrh.  funct., pres. /recent (i.e. last 6 mnths)/sev./danger.bleed. disord., con-  Warnings and special precautions: Use homolog. fibrinolyts.
   Adjunct.ther: Safety and effic.of regim.with concom. heparin &   com.anticoag.ther., CNS damage hist., haemorrhag.stroke/stroke of   when thrombolyt.ther. necess./ high antibody conc.against strep-
   acetylsalicyl.acid dur.first 24 hrs. aft.sympts.onset.not investig.suffic.   any origin at any time, ischaem.stroke/TIA in preced.6 mnths., haem-  tokinase is present/rec.streptokinase ther. has been given (&gt; 5 days
   Acetylsalicyl. acid/IV heparin should be avoid.in first 24 hrs.aft.treatm.   orrhag. diathes., sev.uncontroll.arter. hypertens., maj.surg., biopsy of   & &lt; 1 yr. prev.), system. eff.poss.dur. intracoron./ intra-arter.admin.,
   If heparin reqd.for other indicat. dos.not to exceed 10 000 IU/day SC.  parenchymal organ., signific.trauma dur.last 2 mnths, rec.head/ cran.  risk of ther.in case of life-threaten.thromboembol. events must be
   Contraindications: High haemorr.risk situat.eg. signific. bleed.  trauma, prolong/traumat.cardiopulm. resuscitat. (&gt;2 min) dur last 2   weigh.against the anticip.benef. in cases such as rec. sev.GI bleed-
   disord.present/within 6 mnths., known haemorrhag.diathes., oral   wks., act.pept. ulcerat., arter.aneurysm, known arterial/ven. malfor-  ing e.g.act. pept. ulc./risk of sev.loc.haemorrh.e.g. aortography by
   anticoag.ther., CNS damage hist.in last 3 mnths., hist./evid./ suspic.   mat., neoplasm with incr.bleed.risk, pregn.& lactat., parturit. within   lumbar route/rec.trauma & cardiopulmon. resuscit./invas.ops. e.g.
   of intracran.haemorrhag.incl sub-arachn. haemorrhag., uncontr.arter.  prev.3 days, prev. tenecteplase treatm., pts.&gt;80 yrs/&lt;18 yrs., cardio-  rec. intubat./ punct.of non-compress.vess, IMI, rec. deliv. or abort/
   hypertens., maj.surg./ maj. biopsy/maj.fract./signific.trauma.in past   gen. shock, ac.pericarditis., subac.bact. endocardit., ac.pancreatit  urogenit.tract.dis.with exist.or potent. bleed.sources/known sept.
   6 wks. incl.trauma assoc.with curr.ac.MI, recent trauma to head/  Side effects: Haemorrh.as superfic./intern.bleed. at any site or   thrombot.dis./ sev. atherosclerot.vess.degenerat.. cerebrovasc. dis./
   cranium, CPR &gt; 2 min, obstetric. deliv past 10 days, recent.punct.  body cavity incl.intracran.haemorrh., arrythm. assoc.with reperfus.,   cavern.pulm.dis. e.g.open TB/mitral valve defects or atrial fibrillat.,
   of noncompress. bld. ves., haemorrhag.stroke/stroke of unknown   anaphylact.reacts., eye haemorrh., haemopericard., thrombot.embol.,   re-treatm.with streptokinase ther.&gt; 5 days partic.betw.5 days-12
   origin at any time, sev.liv.dis.incl.hepat.fail./ cirrhos./port.hypertens/  epistax., pulm. haemorrh., GI haemorrh., retroperiton. haemorrh., ec-  mnths.aft.init.treatm.may not be effect.because of poss.resist.due
   oesophag.varices & act. hepatit., infect.endocardit./pericardit., ac.   chymos., urogenit. haemorrh., drop in BP, incr.temp., fat embolisat.,   to antistreptokin.antibod./rec. streptococ.infects., at begin.of ther.
   pancreatit., ulcerat.GI dis.last 3 mnths., arterial aneurysm, arter/  whole bld.transfus.  infus.to be perform.slow.as fall in BP/tachycard./bradycard. observ.,
   ven.malformat., dissect. aort. aneurysm, known/suspect.intracran.  Warnings and special precautions: For use by exper. physic.only,   corticoster.can be admin.prophylact., neutral. prev.hepar.ther.with
   neoplasm, neoplasm with incr bld.risk., ac.stroke in childr.& ado-  resuscitat.equipm.& meds always to be avail., concom.unfraction.  protamine sulph. bef. init.thrombolyt.ther., thrombin time should not
   lesc.und.18 yrs./adults over 80 yrs. Addit.C/I for ac. MI & pulm.  hepar. anticoag. may contribut.to bleed., monit.all poss. bleed.sites,   be more than twice norm.contr.value bef.init. ther., in pts.prev.treat.
   embol.indicat: Ischaem. stroke/ TIA in preced.3 mnths.except.curr.  systol. BP &gt;160 mm Hg, cerebrovasc. dis., rec.(last 10 days) GI/GU   with coumarin derivativ. INR must be &lt; 1.3 bef.start.streptokin.infus.,
   ac. ischaem. stroke within 4,5 hrs. Addit.C/I for ac.ischaem.stroke   bleed., high risk of L heart thrombos., haemostat.defects.incl.those   simultan. ASA ther.has posit.& mutual.reinforc. eff. on life-expect.of
   indicat: Ischaem.attack sympts. more than 4,5 hrs prior infus./when   second. to sev.hepat.dis., rec.(i.e.last 2 days) known IM inj., pts. over   pts.with suspect.MI, admin. of ASA to commen.prior to streptokin.
   time of sympt. onset.unknown, sympts of ac.ischaem. stroke either   75 yrs., bm&lt;60 kg, concom. GPIIb/IIIa antagon.incr.bleed.risk, pts.may   ther.& be contin. for at least 1 mnth., instit.proteinase inhibit. treatm.
   rapid.improv./minor bef.infus.start., sev. stroke.clinic.NIHSS &gt;25/  exper. dis. relat.card.events independ.of treatm.given.  in serious haemorrh.complicat.aft. discont. streptokin.ther., discont.in</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page172.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page168.html">168</a>&nbsp;&nbsp;&nbsp;<a href="page169.html">169</a>&nbsp;&nbsp;&nbsp;<a href="page170.html">170</a>&nbsp;&nbsp;&nbsp;<a href="page171.html">171</a>&nbsp;&nbsp;&nbsp;<a href="page172.html">172</a>&nbsp;&nbsp;&nbsp;<a href="page173.html">173</a>&nbsp;&nbsp;&nbsp;<a href="page174.html">174</a>&nbsp;&nbsp;&nbsp;<a href="page175.html">175</a>&nbsp;&nbsp;&nbsp;<a href="page176.html">176</a>&nbsp;&nbsp;&nbsp;<a href="page177.html">177</a>&nbsp;&nbsp;&nbsp;<a href="page178.html">178</a>
             </td>
             <td width="35%"><a href="page174.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page174.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
